Buy, Sell or Hold: Envista Holdings (NVST-N) — Stock Predictions at Stockchase

NYSE:NVST

42.92

1.14 (2.73%) 1d

Showing 1 to 6 of 6 entries

BUY

She started buying this last year. They revamped their dental product lines, which are doing well. Dental care has room to grown in emerging, markets, though mature in North America. She sees 10% upside one year out. Likes it.

Healthcare

BUY

A past top pick. She likes their long-term growth outlook because of demographics and penetrating emerging markets where dentistry penetration remains low. Danaher spun out Envista to focus more on healthcare R&D, which has worked out. She sees mid-single-digit top-line growth and margin improvement in NVST.

Healthcare

BUY

It got spun out in late 2019. The dental sector has a lot of room to grow as the population ages and needs more dental care in North America. In developing markets there's a lot of room to grow; they need more dental hygiene. ENST has been investing in R&D, previously lagging, and are now leaders in implants. Lots going on. They sell products directly and indirectly, so they have channels to sell new innovative products. Trades at a reasonable PE.

Healthcare

BUY on WEAKNESS

Reported a good quarter. Her target price is closer to $50, so she's not buying it right now. On a weak day, you could start or add to your position.

Healthcare

TOP PICK

Dental products, with a broad range. Spun off from Danaher, allowing them to focus on improvements. Quite global, with only 48% of revenues coming from North America. Leading player in implants, a growing segment. Good growth in both developed and developing markets. Likes the valuation and its industry position. No dividend. (Analysts’ price target is $50.57)

Healthcare

BUY

They make dental products. She likes the dental industry for its secular growth, specifically from aging demographics (a desire to keep your teeth longer which feeds the implant business), and a low penetration rate in developing markets. 22% of their revenues come from emerging markets, plus 50% from North America. There's a lot of room for NVST to grow and they have a broad product offering, supplying 90% of the equipment of what a dentist needs. They lead in many product categories. They just launched the Sparks clear dental liner which is enjoying strong growth int he U.S., the first innovation in years. They're #1 in the implant business. (Analysts’ price target is $51.75)

Healthcare

Showing 1 to 6 of 6 entries

Envista Holdings(NVST-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 5

Stockchase rating for Envista Holdings is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Envista Holdings(NVST-N) Frequently Asked Questions

What is Envista Holdings stock symbol?

Envista Holdings is a American stock, trading under the symbol NVST-N on the New York Stock Exchange (NVST). It is usually referred to as NYSE:NVST or NVST-N

Is Envista Holdings a buy or a sell?

In the last year, 5 stock analysts published opinions about NVST-N. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Envista Holdings.

Is Envista Holdings a good investment or a top pick?

Envista Holdings was recommended as a Top Pick by on . Read the latest stock experts ratings for Envista Holdings.

Why is Envista Holdings stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Envista Holdings worth watching?

5 stock analysts on Stockchase covered Envista Holdings In the last year. It is a trending stock that is worth watching.

What is Envista Holdings stock price?

On 2022-05-17, Envista Holdings (NVST-N) stock closed at a price of $42.92.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.